New drug may offer safer option for rare Muscle-Weakening disease before surgery
NCT ID NCT07231523
First seen Nov 17, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tests whether a newer drug, efgartigimod, works better and is safer than standard intravenous immunoglobulin (IVIG) for people with myasthenia gravis caused by a thymoma tumor. About 64 adults who need surgery to remove the tumor will receive one of the two treatments around the time of their operation. The goal is to see which drug better reduces muscle weakness and improves daily function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EFGARTIGIMOD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.